A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
Status:
Completed
Trial end date:
1993-05-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy, safety and tolerance, and other clinical and immunologic effects of
zidovudine (AZT) plus zalcitabine (dideoxycytidine; ddC), AZT plus didanosine (ddI), and AZT
alternating monthly with ddI as measured by differences in survival among HIV-infected
persons who have received 6 or more months of nucleoside monotherapy and have a CD4 count
greater than or equal to 50 cells/mm3.
Combining two nucleoside drugs has the theoretical advantage of optimal protection against
the evolution of resistant strains of HIV. However, one major problem with combination
nucleoside therapy in patients with advanced disease is the increased toxicity resulting from
such therapy. One approach to minimize toxicity while perhaps retaining some of the benefits
of combination therapy is to alternate the two drugs.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)